Loading candles…
Wockhardt is a global pharmaceutical and biotechnology company involved in drug discovery, manufacturing, and marketing of finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products such as creams and ointments. Its products span multiple therapeutic areas including anti-infectives, diabetes, cardiology, and dermatology. The company conducts dedicated research focused on novel antibiotics to tackle antimicrobial resistance (AMR). Wockhardt operates across key geographies including the UK, USA, and Europe, which represent a significant share of its consolidated revenue.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and Fund Raising | 4 May 2026 |
| Unaudited Results - Q3-FY15 | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board o… | 10 Feb 2026 |
| Results - Q2 & FY25 | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we wish to inform you that a meeting of the Board of… | 3 Nov 2025 |
| Unaudited Results - Q1-FY25 | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board o… | 8 Aug 2025 |
| Audited Results - Q4 & FY25 | Pursuant to Regulation 29(1) (a) and (d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wi… | 29 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.